The US Food and Drug Administration approved a record 32 biotechnology drugs, vaccines and new indications for existing medicines in 2000. Now there are 110 biotech-derived therapeutics on the market and another 350 targeting more than 200 diseases in late-stage development. Millipore technology and expertise is particularly well suited to the purification of biotechnology therapeutics.